帕罗西汀联合阿立派唑对女性精神分裂症伴抑郁症状患者临床症状评分及糖脂代谢的影响

Effects of Paroxetine Combined with Aripiprazole on Clinical Symptom Score and Glucose and Lipid Metabolism in Female Schizophrenic Patients with Depressive Symptoms

目的:探讨帕罗西汀联合阿立哌唑对女性精神分裂症伴抑郁症状患者临床症状评分及糖脂代谢的影响。方法:选择2019年1月—2020年4月惠州市第二人民医院收治的精神分裂症伴抑郁女性患者76例,按随机数字表法分为两组,各38例。对照组给予阿立哌唑治疗,观察组在阿立哌唑基础上联合帕罗西汀治疗,比较两组治疗前及治疗后阳性和阴性症状量表(PANSS)评分、汉密顿抑郁量表(HAMD)评分、糖脂代谢及不良反应。结果:治疗前,两组PANSS及HAMD评分、空腹血糖(FPG)、总胆固醇(TC)、甘油三酯(TG)水平比较,差异无统计学意义(P>0.05);治疗后,观察组PANSS中阳性症状(10.12±2.40)分、阴性症状(14.33±3.25)分、一般精神病理(22.18±4.39)分以及HAMD评分(10.21±3.08)分,均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组FPG(4.66±0.58)mmol/L、TC(4.53±0.96)mmol/L、TG(1.43±0.29)mmol/L,与对照组比较,均无明显差异(P>0.05);观察组治疗后不良反应发生率为15.79%,略低于对照组的18.42%,差异无统计学意义(P>0.05)。结论:帕罗西汀联合阿立哌唑对于降低女性精神分裂症伴抑郁症状患者临床PANSS评分及HAMD评分效果显著,且对糖脂代谢功能无明显影响,安全性较高。

Objective:To investigate the effect of paroxetine combined with aripiprazole on clinical symptom score and glucose and lipid metabolism in female schizophrenic patients with depression.Methods:From January 2019 to April 2020,76 female schizophrenic patients with depression admitted in the hospital were randomly divided into two groups,38 cases in each group.The control group was treated with aripiprazole,and the observation group was treated with paroxetine on the basis of aripiprazole.The positive and negative symptom scale(PANSS)score,Hamilton Depression Scale(HAMD)score,glucose and lipid metabolism and adverse reactions were compared between the two groups before and after treatment.Results:Before treatment,there was no statistically significant difference in PANSS and HAMD scores,fasting blood glucose(FPG),total cholesterol(TC)and triglyceride(TG)levels between the two groups(P>0.05).After treatment,the positive symptoms(10.12±2.40),negative symptoms(14.33±3.25),general psychopathology(22.18±4.39)and HAMD scores(10.21±3.08)in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).After treatment,compared with the control group,there was no statistically significant difference in FPG(4.66±0.58)mmol/L,TC(4.53±0.96)mmol/L and TG(1.43±0.29)mmol/L in the observation group(P>0.05).The incidence of adverse reactions in the observation group was 15.79%,slightly lower than 18.42%in the control group,the difference was not statistically significant(P>0.05).Conclusion:Paroxetine combined with aripiprazole can significantly reduce the PANSS and HAMD scores of female schizophrenic patients with depression,and has no significant impact on the glucose and lipid metabolism function,with high safety.